Equities

Aurisco Pharmaceutical Co Ltd

605116:SHH

Aurisco Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)20.18
  • Today's Change-0.22 / -1.08%
  • Shares traded1.62m
  • 1 Year change-7.52%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments535390445
Total Receivables, Net307241160
Total Inventory510445327
Prepaid expenses3.63118.30
Other current assets, total111.53--
Total current assets1,3661,088940
Property, plant & equipment, net987742717
Goodwill, net------
Intangibles, net12112340
Long term investments795515
Note receivable - long term------
Other long term assets------
Total assets2,5752,0351,721
LIABILITIES
Accounts payable174115137
Accrued expenses534241
Notes payable/short-term debt149650
Current portion long-term debt/capital leases5.146.234.06
Other current liabilities, total1209410
Total current liabilities501322193
Total long term debt721614
Total debt2268718
Deferred income tax0.284.811.92
Minority interest07.991.75
Other liabilities, total347.694.53
Total liabilities607359215
SHAREHOLDERS EQUITY
Common stock406406401
Additional paid-in capital585553492
Retained earnings (accumulated deficit)999773615
Treasury stock - common(46)(57)--
Unrealized gain (loss)------
Other equity, total231.00(1.09)
Total equity1,9681,6761,506
Total liabilities & shareholders' equity2,5752,0351,721
Total common shares outstanding402401401
Treasury shares - common primary issue4.165.200
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.